Last reviewed · How we verify
SPY001-001
At a glance
| Generic name | SPY001-001 |
|---|---|
| Sponsor | Spyre Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis (PHASE2)
- A Study of SPY001-001 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SPY001-001 CI brief — competitive landscape report
- SPY001-001 updates RSS · CI watch RSS
- Spyre Therapeutics, Inc. portfolio CI